Robert Tansley
Partner at Cambridge Innovation Capital
Greater Cambridge Area
Overview
Work Experience
Partner
2014 - Current
Cambridge Innovation Capital backs world-leading life sciences and technology companies with an affiliation to Cambridge, Europe’s leading capital for innovation. As a preferred investor for the University of Cambridge, we have unparalleled access to investment opportunities in the ecosystem. Since our inception in 2013, we have raised over £500 million to invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health and genomics/proteomics.
Board Member
2022
T-Therapeutics is on a mission to unlock the power of T cells to treat a number of areas of unmet medical need
Board Member
2021
Developing treatments to address the genetic roots of mitochondrial dysfunction
Pretzel Therapeutics mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction through mitochondrial biology.
Raised $72,500,000.00 from University of Cambridge Enterprise, Karolinska, Google Ventures, Mubadala Capital Ventures, Angelini Ventures, Invus, EIR Ventures, HealthCap, ARCH Venture Partners and GU Ventures.
Board Member
2017
Exvastat is a drug development company developing a novel treatment for Acute Respiratory Distress Syndrome.
Board Member
2016
A spin-out from the Wellcome Sanger Institute based on world-class science, Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers
Board Observer
2016
Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer. In doing so, we aim to have a major impact on the lives of patients with the greatest unmet need and transform the way that cancer is treated.
Board Member
2020 - 2023
PetMedix is a species-specific antibody discovery and development company focused on the companion animal market. In September 2023, the leading animal health company Zoetis announced that they had acquired PetMedix
Board Member
2015 - 2023
Abcodia is dedicated to transforming clinical care through the earlier detection of cancer. We focus on measuring and modeling dynamic changes in serum-based biomarkers over time. Our first product, the ROCA Test, is a blood test for the early detection of ovarian cancer. In July 2023, Abcodia was acquired by GenIncode.
Board Member (2016-2019), Board Observer (2019-2021)
2016 - 2021
Our aim at CMR Surgical is to make minimal access surgery available to all. With Versius we have designed a next-generation tool to fit seamlessly into today’s operating rooms, working in harmony with the surgeon to improve patient outcomes and deliver value for healthcare providers
Board Member
2014 - 2021
Inivata is a leading liquid biopsy company seeking to improve the management of patients with cancer. In May 2020, NeoGenomics, a leading US oncology diagnostic company took an equity position in Inivata as part of a commercialisation agreement. In June 2021, NeoGenomics acquired the remaining equity that it did not already own in Inivata for $390 million.
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis.
Raised $164,354,305.00 from Janus Henderson Investors, Soleus Capital and Farallon Capital Management.